Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

This study has been completed.
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: September 22, 2011
Last updated: October 26, 2016
Last verified: October 2016

This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected, antiretroviral treatment-naive and treatment-experienced adults with no darunavir (DRV) resistance-associated mutations.

After the Week 48 Visit, participants will be given the option to participate in an open-label rollover phase to receive cobicistat and attend visits every 12 weeks until it becomes commercially available, or until Gilead Sciences elects to terminate development of cobicistat.

Condition Intervention Phase
Acquired Immunodeficiency Syndrome
HIV Infections
Drug: COBI
Drug: DRV
Drug: NRTIs
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Percentage of Participants With Onset of Any Treatment-emergent Grade 3 or 4 Adverse Event Between Baseline and Week 24 [ Time Frame: Up to 24 weeks ]

Secondary Outcome Measures:
  • Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 24 (Snapshot Analysis) [ Time Frame: Week 24 ]
  • Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48 (Snapshot Analysis) [ Time Frame: Week 48 ]
  • Change From Baseline in CD4+ Cell Count at Week 24 [ Time Frame: Baseline; Week 24 ]
  • Change From Baseline in CD4+ Cell Count at Week 48 [ Time Frame: Baseline; Week 48 ]
  • Percentage of Participants Experiencing Any Treatment-emergent Adverse Event and Any Treatment-emergent Adverse Event Leading to Discontinuation of Study Drug Through Week 24 [ Time Frame: Up to 24 weeks ]
  • Percentage of Participants Experiencing Any Treatment-emergent Adverse Event and Any Treatment-emergent Adverse Event Leading to Discontinuation of Study Drug Through Week 48 [ Time Frame: Up to 48 weeks ]

Enrollment: 314
Study Start Date: September 2011
Study Completion Date: October 2015
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: COBI-boosted DRV
Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
Drug: COBI
150 mg tablet administered orally with food once daily
Other Names:
  • Tybost®
  • GS-9350
Drug: DRV
800 mg (2 x 400 mg tablets) administered orally with food once daily
Other Names:
  • Prezista®
  • TMC114
Drug: NRTIs
Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult ≥ 18 years males or non-pregnant females
  • Ability to understand and sign a written informed consent form
  • General medical condition that does not interfere with the assessments and the completion of the trial
  • Treatment Naive: No prior use of any approved or investigational antiretroviral drug for any length of time OR
  • Treatment Experienced: Stable antiretroviral regimen for at least 12 weeks prior to screening
  • Plasma HIV-1 RNA levels ≥ 1000 copies/mL at Screening
  • Screening genotype report shows full sensitivity to two nucleoside analogue reverse transcriptase inhibitors (NRTIs) and no darunavir resistance-associated mutations
  • Normal electrocardiogram (ECG)
  • Hepatic transaminases ≤ 2.5 × upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 mg/dL
  • Adequate hematologic function
  • Serum amylase ≤ 2 × ULN and serum lipase ≤ 3 × ULN
  • Adequate renal function: Estimated glomerular filtration rate ≥ 80 mL/min
  • Females of childbearing potential must agree to utilize protocol-recommended methods of contraception, or be nonheterosexually active, practice sexual abstinence or have a vasectomized partner from Screening throughout the duration of the study period and for 30 days following the last dose of study drug.
  • Male subjects must agree to utilize protocol-recommended methods of contraception during heterosexual intercourse from the Screening visit, throughout the duration of the study and for 30 days following discontinuation of investigational medicinal product or be nonheterosexually active, practice sexual abstinence, or be vasectomized.

Exclusion Criteria:

  • Previous or current use of darunavir
  • A new AIDS-defining condition diagnosed within the 30 days prior to Screening
  • Females who are breastfeeding
  • Positive serum pregnancy test (if female of childbearing potential)
  • Proven or suspected acute hepatitis in the 30 days prior to study entry
  • Subjects receiving drug treatment for hepatitis C virus (HCV), or subjects who are anticipated to receive treatment for HCV during the course of the study
  • Have a history of ongoing active liver disease or experiencing decompensated cirrhosis irrespective of liver enzyme levels
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use that may interfere with subject study compliance
  • A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma
  • Active, serious infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline
  • Participation in any other clinical trial
  • Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements.
  • Subjects receiving ongoing therapy with any of the medications, including drugs not to be used with cobicistat, darunavir, or investigator selected NRTIs; or subjects with any known allergies to cobicistat tablets, darunavir tablets or contraindications for the 2 NRTIs as part of the regimen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01440569

  Hide Study Locations
United States, Arizona
Spectrum Medical Group
Phoenix, Arizona, United States, 85012
United States, California
Long Beach Education and Research Consultants, PC
Long Beach, California, United States, 90813
Peter J Ruane MD Inc.
Los Angeles, California, United States, 90036
Anthony Mills MD Inc
Los Angeles, California, United States, 90069
Stanford University
Palo Alto, California, United States, 94304
Kaiser Permanente Medical Group
Sacramento, California, United States, 95825
La Playa Medical Group and Clinical Research
San Diego, California, United States, 92103
Metropolis Medical
San Francisco, California, United States, 94109
United States, Colorado
Apex Research LLC
Denver, Colorado, United States, 80220
United States, District of Columbia
Dupont Circle Physician's Group
Washington, District of Columbia, United States, 20009
Whitman-Walker Health
Washington, District of Columbia, United States, 20009
United States, Florida
Gary J. Richmond,M.D., P.A.
Fort Lauderdale, Florida, United States, 33316
Midway Immunology and Research Center
Fort Pierce, Florida, United States, 34983
Wohlfeiler, Piperato and Associates, LLC
Miami Beach, Florida, United States, 33139
Orlando Immunology Center
Orlando, Florida, United States, 32803
St. Joseph's Comprehensive Research Institute
Tampa, Florida, United States, 33614
United States, Georgia
Atlanta ID group
Atlanta, Georgia, United States, 30309
Infectious Disease Specialists of Atlanta
Decatur, Georgia, United States, 30033
Mercer University
Macon, Georgia, United States, 31220
United States, Hawaii
Hawaii Center for AIDS, University of Hawaii
Honolulu, Hawaii, United States, 96816
United States, Illinois
Howard Brown Health Center
Chicago, Illinois, United States, 60613
Northstar Medical Center
Chicago, Illinois, United States, 60657
United States, Maryland
Johns Hopkins University
Lutherville, Maryland, United States, 21093
United States, Massachusetts
Community Research Initiative of New England
Boston, Massachusetts, United States, 02215
United States, Michigan
Be Well Medical Center
Berkley, Michigan, United States, 48072
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Central West Clinical Research Inc
St. Louis, Michigan, United States, 63108
United States, Minnesota
HIV Program Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415
United States, New Jersey
Saint Michael's Medical Center
Newark, New Jersey, United States, 07102
South Jersey Infectious Disease
Somers Point, New Jersey, United States, 08244
United States, New York
North Shore University Hospital / Division of Infectious Diseases
Manhasset, New York, United States, 11030
Greiger Clinic
Mt. Vernon, New York, United States, 10550
Beth Israel Medical Center
New York, New York, United States, 10003
United States, North Carolina
Carolinas Medical Center-Myer's Park Infectious Disease Clinic
Charlotte, North Carolina, United States, 28079
Duke University Medical Center
Durham, North Carolina, United States, 27710
Wake Forest University Health Services
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
University of PA
Philadelphia, Pennsylvania, United States, 19104
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States, 19107
United States, Rhode Island
Miriam Hospital
Providence, Rhode Island, United States, 02906
United States, Texas
Central Texas Clinical Research
Austin, Texas, United States, 78705
Trinity Health and Wellness Center/AIDS Arms, Inc.
Dallas, Texas, United States, 75208
Southwest Infectious Disease Clinical Research, Inc.
Dallas, Texas, United States, 75219
Tarrant County Infectious Disease
Fort Worth, Texas, United States, 76104
Therapeutic Concepts, PA
Houston, Texas, United States, 77004
Gordon Crofoot MD, PA
Houston, Texas, United States, 77098
DCOL Center for Clinical Research
Longview, Texas, United States, 75605
United States, Virginia
Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
Annandale, Virginia, United States, 22003
United States, Washington
Swedish Medical Center
Seattle, Washington, United States, 89104
Puerto Rico
Clinical Research Puerto Rico
San Juan, Puerto Rico, 00909
Sponsors and Collaborators
Gilead Sciences
Janssen Research & Development, LLC
Study Director: Marshall Fordyce, MD Gilead Sciences
  More Information

Responsible Party: Gilead Sciences Identifier: NCT01440569     History of Changes
Other Study ID Numbers: GS-US-216-0130
2011-003501-22 ( EudraCT Number )
Study First Received: September 22, 2011
Results First Received: October 23, 2014
Last Updated: October 26, 2016

Keywords provided by Gilead Sciences:
Treatment Naïve
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Slow Virus Diseases
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
HIV Protease Inhibitors
Protease Inhibitors processed this record on April 27, 2017